The Cairo kidney center protocol for rapamycin-based sequential immunosuppression in kidney transplant recipients: 2-year outcomes

Experimental and Clinical Transplantation

Volumn 5, Issue 2, 2007, Pages 649-657

  Barsoum, Rashad S ^a   Morsy, Ahmed A ^a   Iskander, Irene R ^a   Morgan, Manal M ^a   Fayad, Tarek M ^a   Atalla, Nasr T ^a   Wafik, Hani ^a   Grace, Renne A ^a   Adel, Noha ^a   Khalil, Soha S ^a  

^a Cairo Kidney Center   (Egypt)

Author keywords

Cyclosporine; Graft function; Live donors; Mycophenolate mofetil; Renal transplant

Indexed keywords

AMLODIPINE; CARVEDILOL; CEFTAZIDIME; CHOLESTEROL; COTRIMOXAZOLE; CREATININE; CYCLOSPORIN A; FENOFIBRATE; FUROSEMIDE; HLA ANTIGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PRAZOSIN; PREDNISOLONE; RAMIPRIL; RAPAMYCIN; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EGYPT; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROINTESTINAL DISEASE; GLOMERULUS FILTRATION RATE; GRAFT INFECTION; GRAFT RECIPIENT; GRAFT SURVIVAL; HEALTH CARE FACILITY; HEMOGLOBIN BLOOD LEVEL; HERPES; HLA MATCHING; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INTERSTITIAL PNEUMONIA; INTESTINE ULCER; KIDNEY BIOPSY; KIDNEY DONOR; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVING DONOR; LUNG CANCER; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PNEUMONIA; PROSTATE CANCER; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SURVIVAL RATE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TIME; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; CYCLOSPORINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MYCOPHENOLIC ACID; PREDNISOLONE; PROSPECTIVE STUDIES; SIROLIMUS; TREATMENT OUTCOME;

EID: 38549145472     PISSN: 13040855     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Stepkowski SM. Preclinical results of sirolimus treatment in transplant models. Transplant Proc. 2003;35(3 Suppl):219S-226S.
2. Kahan BD, Gibbons S, Tejpal N, Stepkowski SM, Chou TC. Synergistic interactions of cyclosporine and rapamycin to inhibit immune performances of normal human peripheral blood lymphocytes in vitro. Transplantation. 1991;51(1):232-239.
3. Murphy GJ, Bicknell GR, Nicholson ML. The effect of combined rapamycin/ cyclosporine on the changes in pro-fibrotic gene expression that occur during the development of allograft vasculopathy in rats, compared with cyclosporine or rapamycin in isolation. Transpl Int. 2003;16(5)347-353.
4. Shihab FS, Bennett WM, Yi H, Andoh TF. Effect of cyclosporine and sirolimus on the expression of connective tissue growth factor in rat experimental chronic nephrotoxicity. Am J Nephrol. 2006;26(4):400-407.
5. MacDonald AS; RAPAMUNE Global Study Group. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/ cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation. 2001;71(2):271-280.
6. Kahan BD. Sirolimus-based immunosuppression: present state of the art. J Nephrol. 2004; 17(Suppl 8):S32-S39.
7. Tsai MK, Chueh SC, Hu RH, Lee PH. Effect of sirolimus in combination with low-dose cyclosporine and steroids on acute renal allograft rejection. J Formos Med Assoc. 2003;102(2):91-96.
8. Morales JM, Campistol JM, Kreis H, et al. Sirolimus-based therapy, with or without cyclosporine: long-term follow-up in renal transplant patients. Transplant Proc. 2005;37(2):693-696.
9. Kreis H, Oberbauer R, Campistol JM, et al. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol. 2004;15(3):809-817.
10. Gregory CR, Pratt RE, Huie P, et al. Effects of treatment with cyclosporine, FK 506, rapamycin, mycophenolic acid, or deoxyspergualin on vascular muscle proliferation in vitro and in vivo. Transplant Proc. 1993;25(1 Pt 1):770-771.
11. Brook NR, Waller JR, Bicknell GR, Nicholson ML. Cyclosporine and rapamycin act in a synergistic and dose-dependent manner in a model of immunosuppressant-induced kidney damage. Transplant Proc. 2005;37(2):837-838.
12. Yakupoglu YK, Buell JF, Woodle S, Kahan BD. Individualization of immunosuppressive therapy. III. Sirolimus associated with a reduced incidence of malignancy. Transplant Proc. 2006;38(2):358-361.
13. Coenen JJ, Koenen HJ, van Rijssen E, et al. Rapamycin, not cyclosporine, permits thymic generation and peripheral preservation of CD4+ CD25+ FoxP3+ T cells. Bone Marrow Transplant. 2007;39(9):537-545.
14. Ekberg H, Grinyó J, Nashan B, et al. Cyclosporine sparing with mycophenolate mofetil, dadizumab and corticosteroids in renal allograft recipients: the CAESAR Study. Am J Transplant. 2007;7(3):560-570.
15. Allison AC, Eugui EM. Preferential suppression of lymphocyte proliferation by mycophenolic acid and predicted long-term effects of mycophenolate mofetil in transplantation. Transplant Proc. 1994;26(6):3205-3210.
16. Voisard R, Geçgüner L, Baur R, Herter T, Hombach V. Antiproliferative profile of sirolimus and mycophenolate mofetil: impact of the SI/MPL ratio. Int J Cardiol. 2005 Jul 20; 102(3):435-442.
17. Kuypers DR. Benefit-risk assessment of sirolimus in renal transplantation. Drug Saf. 2005;28(2):153-181.
18. MacDonald AS. Rapamycin in combination with cyclosporine or tacrolimus in liver, pancreas, and kidney transplantation. Transplant Proc. 2003;35(3 Suppl):201S-208S.
19. Zimmerman JJ, Harper D, Getsy J, Jusko WJ. Pharmacokinetic interactions between sirolimus and microemulsion cyclosporine when orally administered jointly and 4 hours apart in healthy volunteers. J Clin Pharmacol. 2003;43(10):1168-1176.
20. Bai S, Brunner LJ, Stepkowski SM, Napoli KL, Kahan ED. Effect of low dose cyclosporine and sirolimus on hepatic drug metabolism in the rat1. Transplantation. 2001;71(11):1585-1592.
21. Picard N, Djebli N, Sauvage FL, Marquet P. Metabolism of sirolimus in the presence or absence of cyclosporine by genotyped human liver microsomes and recombinant cytochromes P450 3A4 and 3A5. Drug Metab Dispos. 2007;35(3):350-355.
22. Bai S, Stepkowski SM, Kahan BD, Brunner U. Metabolic interaction between cyclosporine and sirolimus. Transplantation. 2004;77(10):1507-1512.
23. Podder H, Stepkowski SM, Napoli KL, et al. Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. J Am Soc Nephrol. 2001;12(5):1059-1071.
24. Grinyó JM, Cruzado JM. Mycophenolate mofetil and sirolimus combination in renal transplantation. Am J Transplant. 2006;6(9):1991-1999.
25. Flechner SM, Goldfarb D, Solez K, et al. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs. Transplantation. 2007;83(7):883-892.
26. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Symphony - comparing standard immunosuppression to low-dose cyclosporine, tacrolimus, or sirolimus in combination with MMF, daclizumab, and corticosteroids in renal transplantation. Transplantation. 2006;2(suppl 6):83.
27. Srinivas TR, Schold JD, Guerra G, Eagan A, Bucci CM, Meier-Kriesche HU. Mycophenolate mofetil/sirolimus compared to other common immunosuppressive regimens in kidney transplantation. Am J Transplant. 2007;7(3):586-594.
28. Gelens MA, Christiaans MH, van Heum EL, van den Berg-Loonen EP, Peutz-Kootstra CJ, van Hooff JP. High rejection rate during calcineurin inhibitor-free and early steroid withdrawal immunosuppression in renal transplantation. Transplantation. 2006;82(9):1221-1223.
29. Hardinger KL, Brennan DC, Lowell J, Schnitzler MA. Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil. Transpl Int. 2004;17(10):609-616.
30. Johnson RW, Kreis H, Oberbauer R, Brattström C, Claesson K, Eris J. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation. 2001;72(S):777-786.
31. The Organ Procurement and Transplantation Network (OPTN). http://www.optn.org/latestData/step2.asp?. Accessed Dec 6, 2007.
32. Kahan BD, Zimmerman J, Scarola J, Maida B, Camardo J. Kinetic-dynamic correlations of sirolimus and cyclosporine in 438 primary renal transplant recipients. Transplantation. 1999;67(9): S546.
33. Gonçalves GM, Cenedeze MA, Feitoza CQ, et al. Heme oxygenase 1 and renal ischemia and reperfusion injury: the impact of immunosuppressive drug. Int Immunopharmacol. 2006;6(13-14):1966-1972.
34. Pallet N, Thervet E, Le Corre D, et al. Rapamycin inhibits human renal epithelial cell proliferation: effect on cyclin D3 mRNA expression and stability. Kidney Int. 2005;67(6):2422-2433.
35. Reis F, Almeida L, Alcebia T, et al. Isosorbide-5-mononitrate treatment prevents cyclosporin A-induced platelet hyperactivation and the underlying nitric oxide-cyclic guanosine-3′, 5′-monophosphate disturbances. Thromb Res. 2003;110(2-3): 107-115.
36. Sartelet H, Toupance O, Lorenzato M, et al. Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys. Am J Transplant. 2005;5(10):2441-2447.
37. Pinheiro HS, Amaro TA, Braga AM, Bastos MG. Post-rapamycin proteinuria: incidence, evolution, and therapeutic handling at a single center. Transplant Proc. 2006;38(10):3476-3478.
38. Rangan GK. Sirolimus-associated proteinuria and renal dysfunction. Drug Saf. 2006;29(12).1153-1161.
39. Izzedine H, Brocheriou I, Frances C. Post-transplantation proteinurra and sirolimus. N Engl J Med. 2005;353(19):2088-2089.
40. Straathof-Galema L, Wetzels JF, Dijkman HB, Steenbergen EJ, Hilbrands LB. Sirolimus-associated heavy proteinuria in a renal transplant recipient: evidence for a tubular mechanism. Am J Transplant. 2006;6(2):429-433.
41. Koenen HJ, Michielsen EC, Verstappen J, Fasse E, Joosten I. Superior T-cell suppression by rapamycin and FK506 over rapamycin and cyclosporine A because of abrogated cytotoxic T-lymphocyte induction, impaired memory responses, and persistent apoptosis. Transplantation. 2003;75(9):1581-1590.
42. Waller JR, Murphy GJ, Bicknell GR, Toomey D, Nicholson ML. Effects of the combination of rapamycin with tacrolimus or cyclosporin on experimental intimal hyperplasia. Br J Surg. 2002;89(11):1390-1395.
43. Kamar N, Allard J, Ribes D, Durand D, Ader JL, Rostaing L. Assessment of glomerular and tubular functions in renal transplant patients receiving cyclosporine A in combination with either sirolimus or everolimus. Clin Nephrol. 2005;63(2):80-86.
44. Serkova N, Jacobsen W, Niemann CU, et al. Sirolimus, but not the structurally related RAID (everolimus), enhances the negative effects of cyclosporine on mitochondrial metabolism in the rat brain. Br J Pharmacol. 2001;133(6):875-885.
45. Kovarik JM, Curtis JJ, Hricik DE, Pescovitz MD, Scantlebury V, Vasquez A. Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. Transplant Proc. 2006;38(10):3456-3458.